Here are four companies awaiting regulatory decisions in July, as listed by Zacks.
- Puma Biotechnology seeks FDA approval for neratinib — a follow-up treatment for a form of early stage breast cancer. The drug company expects a response from the FDA by the end of the month.
- Ocular Therapeutix‘s drug Dextenza is a treatment for eye pain following ophthalmic surgery. The company expects a response from the FDA July 19.
- Eagle Pharmaceuticals expects to hear from the FDA on July 23 regarding the review of its external heat stroke treatment Ryanodex.
- Amgen and UCB will learn if their osteoporosis drug Evenity earns FDA approval July 19.
More articles on supply chain:
6 drugmakers in the headlines
10 most-read supply chain stories in June
Teens have limited access to emergency contraception: 4 study findings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
